Net Sales at Rs 430.00 crore in December 2025 up 32.31% from Rs. 325.00 crore in December 2024. Quarterly Net Profit at Rs. 28.00 crore in December 2025 up 227.27% from Rs. 22.00 crore in December ...

Net Sales at Rs 888.00 crore in December 2025 up 23.16% from Rs. 721.00 crore in December 2024. Quarterly Net Profit at Rs.

Wockhardt Ltd that built its name as a maker of generic drugs is shifting its focus in the US market to developing new antibiotics, turning away from generics and entering a space largely vacated by ...

MUMBAI (Reuters) - Indian drugmaker Wockhardt Ltd said the U.S. Food and Drug Administration (FDA) had issued a notice outlining manufacturing violations at its Shendra plant in western India, ...

Wockhardt's earnings before interest, tax, depreciation and amortisation (EBITDA) increased 38.3% to ₹177 crore from ₹128 crore in the third quarter of the previous fiscal.

India’s Wockhardt, which has had its financial fortunes dampened for several years by FDA-related manufacturing issues, has decided to improve its cash flow by selling a plant and portfolio of ...

It's strike three for India’s Wockhardt, which has had a third plant in its home country banned from exporting to the U.S. The FDA on Friday added Wockhardt’s bulk manufacturing plant in Ankleshwar, ...

Add Yahoo as a preferred source to see more of our stories on Google. MUMBAI (Reuters) - Drugmaker Wockhardt Ltd (WCKH.NS) is recalling 109,744 bottles of a high blood pressure drug in the United ...

Shares of drug firm Wockhardt are in action even as the benchmark indices declined in early trade on Tuesday, December 2, 2025, amid uncertainty over repo rate cuts. The counter opened in green at Rs ...

Drugmaker Wockhardt has got off to an optimistic start this year with its novel antibiotic nafithromycin (Miqnaf) getting regulatory approval from the Central Drugs Standard Control Organization.

Mumbai: Pharma company Wockhardt is set for a major rejig soon, which could involve a complete sale of its domestic business. The deal size could be around Rs 2,000 crore, sources close to the ...

A federal judge has thrown out generic-drug maker Wockhardt Ltd.'s claim that Sepracor Inc. misled patent examiners by covering up rat study data related to sleep drug Lunesta, saying that the ...